222 related articles for article (PubMed ID: 16835747)
1. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Kanazawa S; Yamaguchi K; Kinoshita Y; Komiyama Y; Muramatsu M; Nomura S
J Cancer Res Clin Oncol; 2006 Nov; 132(11):719-25. PubMed ID: 16835747
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
3. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
Umekawa K; Kimura T; Kudoh S; Suzumura T; Oka T; Nagata M; Mitsuoka S; Matsuura K; Nakai T; Yoshimura N; Kira Y; Hirata K
BMC Res Notes; 2013 Apr; 6():139. PubMed ID: 23566546
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
[TBL] [Abstract][Full Text] [Related]
5. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
Fujiwara Y; Kiura K; Toyooka S; Hotta K; Tabata M; Takigawa N; Soh J; Tanimoto Y; Kanehiro A; Kato K; Date H; Tanimoto M
Lung Cancer; 2008 Jan; 59(1):81-7. PubMed ID: 17765355
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
9. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer.
De Vita F; Turitto G; di Grazia M; Frattolillo A; Catalano G
Tumori; 1998; 84(1):33-8. PubMed ID: 9619711
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
[TBL] [Abstract][Full Text] [Related]
11. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
Qin HF; Qu LL; Liu H; Wang SS; Gao HJ
Asian Pac J Cancer Prev; 2013; 14(7):4205-8. PubMed ID: 23991977
[TBL] [Abstract][Full Text] [Related]
12. Aspirin reduces adverse effects of gefitinib.
Kanazawa S; Yamaguchi K; Kinoshita Y; Muramatsu M; Komiyama Y; Nomura S
Anticancer Drugs; 2006 Apr; 17(4):423-7. PubMed ID: 16550000
[TBL] [Abstract][Full Text] [Related]
13. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Ishikawa N; Daigo Y; Takano A; Taniwaki M; Kato T; Hayama S; Murakami H; Takeshima Y; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
Cancer Res; 2005 Oct; 65(20):9176-84. PubMed ID: 16230376
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of soluble interleukin-2 receptors in small cell lung carcinoma.
Yamaguchi K; Nishimura Y; Kiyokawa T; Matsuzaki H; Ishii T; Kubota K; Kawahara M; Furuse K; Yoshinaga T; Kinuwaki E
J Lab Clin Med; 1990 Oct; 116(4):457-61. PubMed ID: 2170552
[TBL] [Abstract][Full Text] [Related]
16. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Kamiya K; Watanabe M; Kohno M; Izumi Y; Horinouchi H; Kawamura M; Shimada N; Nomori H
Respirology; 2011 Aug; 16(6):976-82. PubMed ID: 21651645
[TBL] [Abstract][Full Text] [Related]
17. Effects of cancer chemotherapy on the relation between serum levels of soluble interleukin-2 receptors and CD4/CD8 ratio in patients with solid neoplasms.
Lissoni P; Barni S; Tancini G; Viviani S; Rovelli F; Rescaldani R; Fiorelli G
J Biol Regul Homeost Agents; 1989; 3(3):131-3. PubMed ID: 2560317
[TBL] [Abstract][Full Text] [Related]
18. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
19. Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Zhuang J; Tang X; Du Z; Yang M; Zhou Y
Talanta; 2016 Nov; 160():636-644. PubMed ID: 27591660
[TBL] [Abstract][Full Text] [Related]
20. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
